Publication
TFF3 is a valuable predictive biomarker of endocrine response in metastatic breast cancer.
Authors not recorded
Endocr Relat Cancer2015PMID 25900183PMC4455223stubpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (5)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 5
- cancerMalignant Breast Neoplasmcivic_curation1.00
- drugAminoglutethimidecivic_curation1.00
- drugTamoxifencivic_curation1.00
- geneTFF3civic_curation1.00
- variantTFF3 EXPRESSIONcivic_curation1.00
Curated evidence
Evidence citing this paper (1)
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 25900183
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| TFF3 EXPRESSION1 | ||||||||
| Aminoglutethimide + TamoxifenSubstitutes | Malignant Breast Neoplasm | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID823TFF3 expression was assessed by IHC in 75 patients, 187 patients were identified for the validation cohort. TFF3 expression was associated with response to endocrine therapy (tamoxifen, aminoglutethim… (full text at CIViC) PMID 25900183 · May et al., 2015 · Open in CIViC | civic |